Lovastatin Nanoparticle Synthesis and Characterization for Better Drug Delivery

Panda, T.

doi:10.2174/1874070701105010028

Cited by 11 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Poor solubility, oral bioavailability, and delivery impact about 40% of medications in development and 70% of synthesized medicinal compounds (1,2). Given a small concentration gradient between the gut and blood arteries, oral administration of drugs with poor solubility results in restricted transport.…”

Section: Introductionmentioning

confidence: 99%

Development and characterization of nanostructure lipid carrier for anti-hepatitis-C virus drug

EL-Badry,

Mahmoud,

Fathalla

et al. 2023

Journal of advanced Biomedical and Pharmaceutical Sciences

View full text Add to dashboard Cite

Velpatasvir (VLP) as, a medication used to treat hepatitis-C virus (HCV). It has a very low oral bioavailability (25%). The aim of the current work is to prepare VLP loaded nanostructured lipid carriers (VLP-NLCs) as a potential way to enhance VLP aqueous solubility and bioavailability and increase its efficacy. The preparation of VLP-NLCs was carried out using the emulsification -solvent evaporation method, followed by ultrasonication. The prepared nanocarrier was examined for its particle size, zeta potential, entrapment efficiency and in-vitro drug release of the selected formula. VLP-NLCs displayed narrow size distribution, spherical morphologies that were nanosized (105 ± 2.3 nm), and significant drug entrapment efficiencies (> 80%). Particle size ranged between 105 ± 2.3 to 1399 ± 2.8 nm and zeta potential between -14.6 ± 0.2 to -46.0 ± 1.1 mV. High entrapping efficiency was obtained due to incorporation of liquid lipid. The In Vitro release showed prolonged time dependent release. NLC 6 had the best results among the eight prepared formulae. These findings show that NLC is a potential carrier to improve the solubility of drug and enhance its bioavailability.

show abstract

Section: Introductionmentioning

confidence: 99%

Development and characterization of nanostructure lipid carrier for anti-hepatitis-C virus drug

EL-Badry,

Mahmoud,

Fathalla

et al. 2023

Journal of advanced Biomedical and Pharmaceutical Sciences

View full text Add to dashboard Cite

show abstract

“…In comparison, the overdose regime might cause unwanted side effects, including myositis and elevation of serum transaminases . In recent years, a range of carriers have emerged for the delivery of LOV, including solid lipid nanoparticles, a solid self-nanoemulsifying drug delivery system, and electrospun fibers, etc. Although several platforms have achieved successes for the efficient drug delivery, the safety of the drug delivery carriers remains a tough concern due to a series of problems caused by the synthetic or exogenous materials, including immunogenicity, biocompatibility, excretion, and degradation .…”

Section: Introductionmentioning

confidence: 99%

Rational Design of Lovastatin-Loaded Spherical Reconstituted High Density Lipoprotein for Efficient and Safe Anti-Atherosclerotic Therapy

Jiang

Tang

et al. 2019

Mol. Pharmaceutics

View full text Add to dashboard Cite

Reconstituted high density lipoprotein (rHDL) is a biomimetic nanoparticle with plaque targeting and anti-atherosclerotic efficacy. In this work, we report on a strategy to rational design of lovastatin (LOV)-loaded spherical rHDL (LOV-s-rHDL) for efficient and safe anti-atherosclerotic therapy. Briefly, three LOV-s-rHDLs were formulated with LOV/s-rHDL at ratios of 8:1, 10:1, and 15:1 upon their respective median-effect values (D m). The combined inhibitory effect between LOV and s-rHDL of different LOV-s-rHDL formulations on DiI-labeled oxLDL internalization was systemically investigated in RAW 264.7 cells based on the median-effect principle. Median-effect analysis demonstrated that the optimized LOV-s-rHDL was formulated with a ratio of 10:1 (D m LOV:D m s‑rHDL), in which LOV and s-rHDL carrier showed the best synergistic effect, presumably ascribed to their inhibitory effect on CD36 and SR-A expression according to the Western blot analysis. In vivo pharmacodynamics studies showed that the optimized LOV-s-rHDL displayed the most pronounced anti-atherosclerotic effect on decreasing plaque area and reducing the MMP level following an 8-week dosing regimen. In vivo atherosclerotic plaque targeting analysis revealed that s-rHDL had potent plaque targeting efficacy, probably owing to the interaction between apoA-I and scavenger receptor B-I. Furthermore, we observed that the optimized LOV-s-rHDL exhibited a favorable safety profile as evidenced by the results of a hemolysis assay, cell cytotoxicity study, and in vivo safety test. Collectively, the rational design of the biomimetic LOV-s-rHDL based on the median-effect analysis provides an efficient strategy to achieve a synergistic and safe anti-atherosclerotic therapy.

show abstract

Zerumbone liquid crystalline nanoparticles protect against oxidative stress, inflammation and senescence induced by cigarette smoke extract in vitro

Paudel,

Clarence,

Panth

et al. 2023

Naunyn-Schmiedeberg's Arch Pharmacol

View full text Add to dashboard Cite

The purpose of this study was to evaluate the potential of zerumbone-loaded liquid crystalline nanoparticles (ZER-LCNs) in the protection of broncho-epithelial cells and alveolar macrophages against oxidative stress, inflammation and senescence induced by cigarette smoke extract in vitro. The effect of the treatment of ZER-LCNs on in vitro cell models of cigarette smoke extract (CSE)-treated mouse RAW264.7 and human BCi-NS1.1 basal epithelial cell lines was evaluated for their anti-inflammatory, antioxidant and anti-senescence activities using colorimetric and fluorescence-based assays, fluorescence imaging, RT-qPCR and proteome profiler kit. The ZER-LCNs successfully reduced the expression of pro-inflammatory markers including Il-6, Il-1β and Tnf-α, as well as the production of nitric oxide in RAW 264.7 cells. Additionally, ZER-LCNs successfully inhibited oxidative stress through reduction of reactive oxygen species (ROS) levels and regulation of genes, namely GPX2 and GCLC in BCi-NS1.1 cells. Anti-senescence activity of ZER-LCNs was also observed in BCi-NS1.1 cells, with significant reductions in the expression of SIRT1, CDKN1A and CDKN2A. This study demonstrates strong in vitro anti-inflammatory, antioxidative and anti-senescence activities of ZER-LCNs paving the path for this formulation to be translated into a promising therapeutic agent for chronic respiratory inflammatory conditions including COPD and asthma.

show abstract

Lovastatin Nanoparticle Synthesis and Characterization for Better Drug Delivery

Cited by 11 publications

References 11 publications

Development and characterization of nanostructure lipid carrier for anti-hepatitis-C virus drug

Development and characterization of nanostructure lipid carrier for anti-hepatitis-C virus drug

Rational Design of Lovastatin-Loaded Spherical Reconstituted High Density Lipoprotein for Efficient and Safe Anti-Atherosclerotic Therapy

Zerumbone liquid crystalline nanoparticles protect against oxidative stress, inflammation and senescence induced by cigarette smoke extract in vitro

Contact Info

Product

Resources

About